Efficacy and Safety Study of the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis

Study identifier:D3256C00001

ClinicalTrials.gov identifier:NCT04605094

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study with a 36–week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications (The HILLIER Study)

Medical condition

Atopic Dermatitis

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

194

Study type

Interventional

Age

12 Years - 130 Years

Date

Study Start Date: 12 Nov 2020
Primary Completion Date: 25 Apr 2022
Study Completion Date: 13 Sept 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA

Inclusion and exclusion criteria